Overview

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology.

Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment.

The company is headquartered in Kraków, Poland. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology. Our work is defined by deep scientific knowledge, organizational efficiency, and a high throughput discovery engine platform.

Our lead candidate, SEL120, is a selective CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in Phase 1/2 clinical development for the treatment of acute myeloid leukemia.

Early pipeline candidates include candidates developed in the area of kinases, cancer metabolism, synthetic lethality and immuno-oncology.

AT RYVU WE:

DISCOVER
INNOVATE
IMPROVE
CARE
PUSH BOUNDARIES

We take pride in our work and strive toward achieving a meaningful impact on patient care.

Management

Scientific Advisory Board

Supervisory Board

Collaborations

Awards

  • Economic Award of the President of Poland

    16/08/2018
  • Economic Award of the President of Poland

    22/08/2019

CSR

  • Unicorn

    http://www.selvita.com

    Lorem ipsum, dolor sit amet consectetur adipisicing elit. Corrupti quisquam quod ab cumque quasi neque praesentium ipsum, atque autem quia blanditiis delectus nulla earum mollitia eum placeat vitae numquam optio?

  • Unicorn

    http://www.selvita.com

    Lorem ipsum, dolor sit amet consectetur adipisicing elit. Corrupti quisquam quod ab cumque quasi neque praesentium ipsum, atque autem quia blanditiis delectus nulla earum mollitia eum placeat vitae numquam optio?

  • Unicorn

    http://www.selvita.com

    Lorem ipsum, dolor sit amet consectetur adipisicing elit. Corrupti quisquam quod ab cumque quasi neque praesentium ipsum, atque autem quia blanditiis delectus nulla earum mollitia eum placeat vitae numquam optio?